Vitamin B12 Injections
and Elevated Cobalt Levels
A new study, "An Autism Cohort Study of Cobalt Levels Following Vitamin
B12 Injections", published in the most recent issue of the peer-reviewed Toxicological &
Environmental Chemistry , confirms a significant association between the frequency of
methylcobalamin (vitamin B12) injections and blood/urinary cobalt levels in subjects diagnosed with
an autism spectrum disorder as well as a significant association between cobalt exposure and damage
to human neurons.
It was previously suggested by investigators that methylcobalamin (the methyl form of vitamin B12
[methyl B12]) injections may play an important role in the treatment of subjects diagnosed with an
autism spectrum disorder. It was determined that the typical dosage of injected methsyl B12 (75 mcg/kg
bodyweight) utilized in subjects diagnosed with an autism spectrum disorder results in an
instantaneous exposure to cobalt equal to about 25% of the entire normal body-burden of cobalt, and
that this exposure is to be repeated every several days for an indefinite period of time. The aim of this
new study was to evaluate the potential effects of methyl B12 injections on cobalt levels in a cohort of
subjects diagnosed with an autism spectrum disorder.
The results of the study showed subjects diagnosed with an autism spectrum disorder receiving
injected methyl B12 at least once every three days had significant increased average levels of cobalt in
the blood (6.83-fold) and urine (51-fold) in comparison to subjects not receiving injected methyl B12.
Further, the more frequently the methyl B12 was injected, the higher the observed cobalt levels in the
blood and urine were. Overall, the subjects receiving injected methyl B12 every second day had
average blood and urinary cobalt levels in excess of the cobalt maximal occupational exposure limits.
Finally, the study also found that inorganic cobalt was able to induce significant damage to human
neurons in a dose-dependent manner.
The present study is the first of its kind to evaluate the potential distribution patterns of cobalt in the
human body following injected methyl B12, as well as the potential toxic consequences of cobalt to
human tissue culture cells. The investigators concluded, "... there may be significant potential benefits
to the administration of methylcobalamin to subjects diagnosed with an ASD ..." but, "... it is
important that physicians prescribing methylcobalamin injections for subjects should routinely monitor
blood and urine cobalt levels, and, to be safe, ensure that their dosing regimens do not result in blood
and/or urine cobalt levels in excess of maximal exposure safety limits. These concerns and caveats
are all important in light of the rapid expansion of the use of methylcobalamin injections in the
treatment of a number of different conditions."
These investigators commented that sublingual preparations containing 50 mcg of methyl B12 per dose
administered to subjects diagnosed with an autism spectrum disorder on a daily basis were found to
induce apparently adequate blood levels of vitamin B12 in the recipients even though their blood/urine
levels were usually below the limits of detection in the lab testing of their blood/urine samples.
This landmark study was supported by the not-for-profit 501(c) 3 corporations: CoMeD, Inc and the
Institute of Chronic Illnesses, Inc.
Your generous tax-free donations will help us to fund additional research, similar to the present study.
May 3, 2010